Japanese Journal of Ophthalmology

, Volume 51, Issue 3, pp 191–196 | Cite as

Infliximab Treatment for Ocular and Extraocular Manifestations of Behçet's Disease

  • Massimo Accorinti
  • Maria Pia Pirraglia
  • Maria Pia Paroli
  • Roberta Priori
  • Fabrizio Conti
  • Paola Pivetti-Pezzi



To assess the efficacy and safety of infliximab in the treatment of sight-threatening uveitis and extraocular manifestations in patients with Behçet's disease.


Twelve patients with Behçet's disease and uveitis were treated with infliximab after unsuccessful therapy with other immunosuppressive drugs. The main outcome measures were as follows: the number of uveitis relapses, the number of Behçet's disease-related extraocular lesions, and the amount of corticosteroids administered during the treatment as well as during an equal prior period of time while the patients were on other immunosuppressive agents. Visual acuity was recorded at the beginning of infliximab therapy and at the end of follow-up, and was defined as stable if it did not change from baseline, increased if it showed at least one line of improvement from baseline, and decreased if it showed at least a one line decrease from baseline.


During an average follow-up of 16.67 ± 7.63 months (median, 15 months), 11 patients (91.6%) showed a reduction in the number of ocular relapses (relapse/month, from 0.35 ± 0.17 to 0.12 ± 0.17, P < 0.001). All of the patients (n = 11) who were taking corticosteroids before infliximab were able to reduce the amount of corticosteroids taken daily during infliximab treatment (from 24.33 ± 10.84 mg/prednisone per day to 8.97 ± 6.81 mg/prednisone per day, P < 0.001), and all presented with a reduced onset of extraocular manifestations of Behçet's disease (mean total number, from 2.83 ± 3.61 to 1.51 ± 2.35, P = 0.039). One patient, who had to stop treatment 2 months after starting because of the onset of pulmonary tuberculosis, showed the same number of relapses during infliximab treatment but was able to reduce the mean daily corticosteroid dose. Visual acuity increased by one or more lines in three eyes (12.5%) and remained unchanged in 87.5% of the eyes. Infliximab-related side effects appeared in four patients (33.3%).


Infliximab was effective in the treatment of uveitis in these Behçet's disease patients, significantly reducing the number of ocular relapses and making possible a significant reduction in the daily dose of corticosteroids administered. Extraocular manifestations of Behçet's disease were also controlled by infliximab. Nevertheless, side effects were not uncommon, and an extensive study of systemic conditions before infliximab administration had to be carried out to exclude systemic infection, particularly prior tuberculosis. Jpn J Ophthalmol 2007;51:191–196 © Japanese Ophthalmological Society 2007

Key words

anti-TNFα therapy Behçet's disease infliximab uveitis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Behçet, H 1937Über rezidivierende Aphthose, durch ein Virus verurusachte Geschwüre in Mund, am Auge und an den GenitalienDematol Wochenschr10511521157Google Scholar
  2. 2.
    Pivetti-Pezzi, P, Gasparri, V, De Liso, P, Catarinelli, G 1985Prognosis in Behçet's diseaseAnn Ophthalmol172025PubMedGoogle Scholar
  3. 3.
    Whitcup, SM, Salvo, EC,Jr, Nussenblatt, RB 1994Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's diseaseAm J Ophthalmol1183945PubMedGoogle Scholar
  4. 4.
    Kaklamani, VG, Vaiopoulos, G, Kaklamanis, PG 1998Behçet's diseaseSemin Arthritis Rheum27197217PubMedCrossRefGoogle Scholar
  5. 5.
    Boyd, SR, Young, S, Lightman, S 2001Immunopathology of the noninfectious posterior and intermediate uveitisSurv Ophthalmol46209233PubMedCrossRefGoogle Scholar
  6. 6.
    Turan, B, Gallati, H, Erdi, H, Gurler, A, Michel, BA, Viligger, PM 1997Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: soluble TNFR-75 as a biological marker of disease activityJ Rheumatol24128132PubMedGoogle Scholar
  7. 7.
    Santos Lacomba, M, Marcos Martin, C, Gallardo Gallera, JM,  et al. 2001Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitisOphthalmic Res33251255PubMedCrossRefGoogle Scholar
  8. 8.
    Chronopoulou, H, Tzavara, V, Oikonomopoulos, N,  et al. 2001High levels of TNF-α in the aqueous humor in patients suffering from Adamantiades-Behçet's disease: preliminary resultsInvest Ophthalmol Vis Sci42S708Google Scholar
  9. 9.
    Sfikakis, PP, Theodossiadis, PG, Katsiari, CG, Kaklamanis, P, Markomichleakis, NN 2001Effect of infliximab on sight-threatening panuveitis in Behçet's diseaseLancet358295296PubMedCrossRefGoogle Scholar
  10. 10.
    Munoz-Fernandez, S, Hidalgo, V, Fernandez-Melon, J, Schlinker, J, Martin-Mola,  2001Effect of infliximab on threatening panuveitis in Behçet's diseaseLancet3581644PubMedCrossRefGoogle Scholar
  11. 11.
    Sfikakis, PP 2002Behçet's disease: a new target for anti-tumor necrosis factor treatmentAnn Rheum Dis61ii51ii53PubMedGoogle Scholar
  12. 12.
    Triolo, G, Vadalà, M, Accardo-Palumbo, A,  et al. 2002Anti-tumor necrosis factor monoclonal antibody treatment for ocular Behçet's diseaseAnn Rheum Dis61560561PubMedCrossRefGoogle Scholar
  13. 13.
    Andreu, M, Ramanoelina, J, Fajnkuchen, F,  et al. 2002Traitment de la maladie de Behçet sèvére par un anti-TNFα: l'infliximabAnn Med Interne153414415Google Scholar
  14. 14.
    Joseph, A, Raj, D, Dua, HS, Powell, PT, Lanyon, PC, Powell, RJ 2003Infliximab in the treatment of refractory posterior uveitisOphthalmology11014491453PubMedCrossRefGoogle Scholar
  15. 15.
    Ohno, S, Nakamura, S, Hori, S,  et al. 2004Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitisJ Rheumatol3113621368PubMedGoogle Scholar
  16. 16.
    Sfikakis, PP, Kaklamanis, PH, Elezoglou, A,  et al. 2004Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet's diseaseAnn Intern Med140404406PubMedGoogle Scholar
  17. 17.
    Tugal-Tutkun, I, Mudun, A, Urgancioglu, M,  et al. 2005Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. An open-label trialArthritis Rheum5224782484PubMedCrossRefGoogle Scholar
  18. 18.
    Benitez-del-Castillo, JM, Martinez-de-la-Casa, JM, Pato-Cotor, E,  et al. 2005Long-term treatment of refractory posterior uveitis with anti-TNF α (infliximab)Eye19841845PubMedCrossRefGoogle Scholar
  19. 19.
    Lindsted, EW, Baarsma, GS, Kuijpers, RWAM, van Hagen, PM 2005Anti-TNFα therapy for sight-threatening uveitisBr J Ophthalmol89533536CrossRefGoogle Scholar
  20. 20.
    Elliott, MJ, Maini, RM, Feldmann, M,  et al. 1994Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritisLancet34411051110PubMedCrossRefGoogle Scholar
  21. 21.
    Lipsky, PE, van der Heijde, DMF, St Claire, EW,  et al. 2000Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritisN Engl J Med34315941602PubMedCrossRefGoogle Scholar
  22. 22.
    Targan, SR Hanauer, SB van Deventer, SJ Crohn's disease cA2 Study Group et al. 1997A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's diseaseN Engl J Med33710291035PubMedCrossRefGoogle Scholar
  23. 23.
    Scallon, B, Cai, A, Solowski, N,  et al. 2002Binding and functional comparison of two types of tumor necrosis factor (TNF) antagonistJ Pharmacol Exp Ther301418426PubMedCrossRefGoogle Scholar
  24. 24.
    International Study Group for Behçet's Disease1990Criteria for diagnosis of Behçet's DiseaseLancet33510781080Google Scholar
  25. 25.
    Masuda, K, Nakajima, A, Urayama, A, Nakae, K, Kogure, M, Inaba, G 1989Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behçet's diseaseLancet110931096PubMedCrossRefGoogle Scholar
  26. 26.
    Hamuryudan, V, Ozyazgan, Y, Hizli, N,  et al. 1997Azathioprine in Behçet's syndrome: effects on long-term prognosisArthritis Rheum40769774PubMedCrossRefGoogle Scholar
  27. 27.
    Pivetti-Pezzi, P, Accorinti, M, Pirraglia, MP, Priori, R, Valesini, G 1997Interferon alpha for ocular Behçet's diseaseActa Ophthalmologica Scand75720722CrossRefGoogle Scholar
  28. 28.
    Okada, AA 2000Drug therapy in Behçet's diseaseOcul Immunol Inflamm130774781Google Scholar
  29. 29.
    Goldstein, DA, Fontanilla, FA, Kaul, S, Sain, O, Tessler, HH 2002Long-term follow-up of patients treated with short-term high-dose chlorambucil for sight-threatening ocular inflammationOphthalmology109370377PubMedCrossRefGoogle Scholar
  30. 30.
    Kotter, I, Zierhut, M, Eckstein, AK,  et al. 2003Human recombinant interferon alpha 2a for the treatment of Behçet's disease with sight-threatening posterior or panuveitisBr J Ophthalmol87423431PubMedCrossRefGoogle Scholar
  31. 31.
    Murphy, CC, Ayliffe, WH, Booth, A, Makanjula, D, Andrews, PA, Jayne, D 2004Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritisOphthalmology111352356PubMedCrossRefGoogle Scholar
  32. 32.
    Saulsbury, FT, Mann, JA 2003Treatment with infliximab for a child with Behçet's diseaseArthritis Rheum49599600PubMedCrossRefGoogle Scholar
  33. 33.
    Licata, G, Pinto, A, Tuttolomondo, A,  et al. 2003Anti-tumor necrosis factor a monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndromeAnn Rheum Dis62280281PubMedCrossRefGoogle Scholar
  34. 34.
    Charles, P, Elliott, MJ, Davis, D,  et al. 1999Regulation of cytokines, cytokine inhibitors, and acute phase proteins following anti-TNF-alpha therapy in rheumatoid arthritisJ Immunol16315211528PubMedGoogle Scholar
  35. 35.
    Perez-Guijo, V, Santos-Lacomba, M, Sanchez-Hernandez, M,  et al. 2004Tumor necrosis factor-alpha levels in aqueous humor and serum from patients with uveitis: the involvement of HLA-B27Curr Med Res Opin20155157PubMedCrossRefGoogle Scholar
  36. 36.
    Keane, J, Gershon, S, Wise, RP,  et al. 2001Tuberculosis associated with infliximab, a tumor-necrosis factor alpha-neutralizing agentN Engl J Med34510981104PubMedCrossRefGoogle Scholar
  37. 37.
    Lim, WS, Powell, RJ, Johnston, ID 2002Tuberculosis and treatment with infliximabN Engl J Med346623626PubMedCrossRefGoogle Scholar
  38. 38.
    Khanna, D, McMahon, M, Furst, DE 2004Safety of tumor necrosis factor-α antagonistsDrug Safety27307324PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2007

Authors and Affiliations

  • Massimo Accorinti
    • 1
  • Maria Pia Pirraglia
    • 1
  • Maria Pia Paroli
    • 1
  • Roberta Priori
    • 2
  • Fabrizio Conti
    • 2
  • Paola Pivetti-Pezzi
    • 1
  1. 1.Servizio di Immunovirologia Oculare, Dipartimento di Scienze OftalmologicheUniversità degli Studi di Roma “La Sapienza”RomeItaly
  2. 2.Dipartimento di ReumatologiaUniversità degli Studi di Roma “La Sapienza”RomeItaly

Personalised recommendations